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(range: 5–20). In 75% of symptomatic patients catheterization, have been described 90–100% stenosis of at least one artery. The
anterior descending branch was affected in 70% of such patients.
Objetives. The heart is an organ at risk incorrectly deﬁned today as a solid organ. Since it is the anterior wall of the VI which
receive 50% or more of the dose, we think the proper contouring of the left coronary artery and its branches, as well as the
left ventricular wall, embryological, histological, anatomical and functionally compromised structures that should be taken into
account when a correct delimitation it is done, key aspect in reducing the long-term cardiac events produced in breast cancer
patients treated with radiotherapy.
Methods.We brieﬂy reviewall aspects of normal left ventricular structure and Standardizedmyocardial segmentation andnomen-
clature for tomographic imaging of the heart of American Heart Association. We outline the whole heart (A), the heart with its
four chambers (B), only the left ventricle (C) and anterior descending coronary artery in ﬁve women, which had been made a CT
with IV contrast for radiotherapy planning of esophageal carcinoma. We compared the maximum, minimum, mean dose, Vx.
Results. All doses vary signiﬁcantly if we outline in the ways previously mentioned, being the most anatomically correct LV
sole contouring although dose unfavorable. With the delineation of anterior descending coronary proximal, middle and distal,
maximum, mean and minimum doses were similar. The anterior descending coronary 65% of its length receives more than 50%
of the dose.
Conclusions. The correct contouring should be limited to cardiac anterior wall of the left ventricle and the coronary artery, the
conformation of the ﬁelds, the techniquewill be oriented to themaximumpreservation of these two structures. Note the probably
damage of cardiac stem cells source at epicardium, and therefore the possible regenerative cell therapy for myocardial injury
and the formation coronary vessels.
http://dx.doi.org/10.1016/j.rpor.2013.03.076
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Introduction. Standard fractionation RT is widely used for breast cancer treatments. Nevertheless, the same level of efﬁcacy and
security has been demonstrated with altered fractionations in terms of local control and toxicity rates. Goals: Evaluation of acute
tolerance, late effects, and efﬁcacy of hypofractionated treatments on breast cancer patients.
Material and methods. From February 2012, seventeen breast cancer patients staged pT1-T2, N0-1, M0 have received 3D planned
adjuvant radiotherapy with a fractionation schedule of 15 fractions of 2.67Gy up to a total dose of 40Gy during three weeks after
tumorectomy, sentinel node biopsy or axillary node dissection (2 patients). Two patients received a boost on the surgical bed
subsequently. Weekly consultations during treatment have been performed in order to evaluate treatment tolerance.
Results. Mean age was 67.5 y.o. (50–84). Stage distribution was 68.7% stage I and 31.7% stage II. Most patients had Inﬁltrating
Ductal Carcinoma (75%), followed by Inﬁltrating Lobular Carcinoma (18,7%) and Mucinous Carcinoma (6,2%). Histologic grade
was % Grade I (56.2%), Grade II (37.5%) or Grade III (6.2%). Two patients received adjuvant chemotherapy whereas the whole
group has received hormonal treatments. Cutaneous toxicity, graded with RTOG scale, grade 1 (43.7%), and grade 2 (12.5%). No
grade 3 radiodermatitis has been observed.
Conclusion. Hypofractionated adjuvant breast irradiation allows the shortage of the radiotherapy course without an increment in
the cutaneous toxicity burden. The study is progressing in order to asses the local control rates and late effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.077
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Introduction. In February 2012 the project LIFE (INNPRONTA) is approved by the Council ofMinisters at the request of the CDTI. This
program represents a qualitative leap in R & D collaboration between ﬁrms and research organizations. Companies participating
in the LIFE project are: ERESA (consortium leader), Genome Systems, Gem-Imaging, IUCT, Instituto Cartuja, Proton Bilbomática
and Laser Applications.
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Objectives. The LIFE project, with a global, multidisciplinary and integral perspective aims to help optimize the entire process
involved in breast cancer from early diagnosis to treatment. The strategy seeks to tailor treatment to each patient’s tumor
molecular characteristics developing a personalized medicine. We present the program to follow during the 4 years of the project
and the partial advances that have been made.
Material and methods. ERESA will develop the Radiotherapy part of the project. The lines of work in this area are: • Implementa-
tion of technology to reduce the volume to be irradiated: – Marking tumor bed – Image guided radiotherapy – Development of
techniques for Partial Breast Irradiation including electron intensity modulation. •Implementation of accelerated hypofraction-
ation. • Development of methods for determining toxicities. These activities will be integrated into the framework of the Breast
Functional Unit of the hospital which has been provisioned with a system of communication and data exchange.
Results. We will use the presentation of the progress made in this period to show the lines of work followed by radiotherapy and
the remaining areas: Research of microRNA proﬁling, development of molecular imaging equipment, characterizing markers in
magnetic resonance spectroscopy, implementation of new drugs, IGRT for Radiotherapy, tracking of optimization techniques in
radiotherapy, etc.
Conclusions. The presentation of this work allows to show the challenge to be faced in the implementation of the LIFE project,
especially in radiotherapy in order to discuss hypotheses and partial results.
http://dx.doi.org/10.1016/j.rpor.2013.03.078
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Introduction. The Radiation Oncology Unit in Alcazar de San Juan is entailed to La Mancha Centro & Tomelloso General Hospitals
and other rural populations, attends a health area of 202.522 in-habitants with a population density of 43.8hab/km2 and a
median travel time of 30min. Benchmarking studies allow comparison of patterns of care and outcomes between different
settings. Design: Retrospective data analysis from a prospective treatment registry. Study period from January to December 2010.
Objective. Estimate the unit workload due to breast cancer. Compare results with those of the GEORM survey (1).
Patients and methods. 93 patients with breast cancer diagnosis were submitted from the Multidisciplinary Tumor Board of La
Mancha Centro for radiotherapy and were identiﬁed from a total of 324 pts (28.%) sent for treatment evaluation. 13% of pts were
treatedwith palliative intention andwere excluded from further analysis. CT based planningwas use in all patients and treated in
supine position with customized alpha-cradle immovilization system and 4 MV photons ± electron ﬁeld 3DCRT. Inverse planning
IMRT was used in 1% pts. Characteristics for 81 pts included: Median age (61 y (R:34-87). BCT in 84% and Mastectomy in 16% (31%
with immediate breast reconstruction). ALND: 35%, SLND only 20%, SLND+ALND: 38%. Pathology: Invasive ductal 79%, Lobulillar
8%, DCIS 4%. Hyostological Grade 1–2: 47%. Nodal positive: 38%. pStage I: 36&, pStage II: 35%. Treatment: Hypofractionation
(START-B): 39%. Boost: 64% (electron ﬁeld in 48%). Nodal volume included in 23% (IMC in 2%).
Conclusion. Patient demographics and tumor characterisitcs are very similar between our results and the GEORM survey, as are
the distribution of radiation techniques used, with an increased use of hypofractionation in our Centre. Our results are aligned
with national patterns of care in breast cancer radiotherapy. 1.- Algara M. on the behalf of the Breast Cancer Radiation Oncology
Spanish Group (GEORM): Radiation techniques used in patients with breast cancer: Results of a survey in Spain. Rep Pract Oncol
Radiother 17:122, 2012.
http://dx.doi.org/10.1016/j.rpor.2013.03.079
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Introduction. The new techniques in breast irradiation, make necessary the implementation of systems that help us to ensure the
proper application of the treatment.
Objective. To show the improvements in quality, time and accuracy in breast cancer radiotherapy (RT) treatments, thanks to the
image guided system AlignRT.
